Multiple pharmaceutical companies disclose progress in new drug development. Thirteen companies are investigated by institutions in a concerted manner and receive increased funding.

Based on the disclosures of listed companies on investor interaction platforms or official platforms so far this year, Data Treasure has compiled the research and development progress of nearly 70 pharmaceutical and biotech companies, involving Western medicine, traditional Chinese medicine, and medical diagnostics. The indications include metabolic diseases, immune diseases, Alzheimer's disease, cardiovascular and cerebrovascular diseases, among others. By counting the number of interactive Q&A sessions, companies that have attracted high investor attention include Betta Pharmaceuticals, Runto Stock, Zhendong Pharmaceutical, and Guangshengtang. Among the pharmaceutical and biotech companies that have disclosed progress in innovative drugs, as of August 8th, more than 30 institutions have conducted research on 30 companies this year. 13 companies have seen a more than 30% increase in the positions held by financing clients this year. Five companies have been researched by over 150 institutions this year, including JW Therapeutics - U, BeiGene - U, Haoyuan Medicine, Taien Health, and Health Yuan.